May 29, 2015.
Reuters reports that China's drug regulator has steeply raised the fees required to register drugs
and medical devices in the world's second-biggest pharmaceutical market, as a lack of resources and expertise hinders its ability to process a rising number of applications. A statement this week from China's Food and Drug Administrator (CFDA) stated that a registration of new locally made drug will soar to 624,000 yuan (US$100,637) compared with 35,000 yuan (US$5,700) in 2013. The cost to register a new imported drug will be about US$156,423, according to the regulator. Generic drugs will cost US$81,897 for domestic drugs to $140,247 for imported products. Reuters reports that China is struggling with a growing backlog of drugs waiting for approval. "There were more than 18,500 drugs in line at end of 2014, up by a third from a year before, reflecting industry concern that it is getting harder to get medicines approved."
http://www.reuters.com/article/2015/05/28/china-pharmaceuticals-idUSL3N0YJ1C020150528
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.